Business Context and Reporting Period
This Form 8-K is filed by Xcyte Therapies, Inc. (not Bio Green Med Solution, Inc.) for the reporting period of June 6, 2005. The company is incorporated in Delaware and headquartered in Seattle, Washington. The filing addresses a regulatory notice regarding the continued listing of its securities on The Nasdaq National Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the market price of the company's common stock, which has closed below the minimum $1.00 per share requirement for 30 consecutive business days.
Material Changes
The material change reported is the receipt of a notice from the Nasdaq Stock Market indicating a failure to satisfy the minimum bid price requirement under Marketplace Rule 4450(a)(5). This status change triggers a potential delisting process if compliance is not restored.
Outlook, Risks, and Contingencies
- Compliance Period: Xcyte has been granted 180 calendar days, until December 5, 2005, to regain compliance.
- Compliance Requirement: To remain listed, the bid price of common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days before the deadline.
- Transfer Option: If the company meets initial inclusion criteria for The Nasdaq SmallCap Market (excluding the $1.00 bid price) by December 5, 2005, it may apply to transfer its listing, potentially gaining an additional 180-day compliance period.
- Delisting Risk: If the company fails to regain compliance or transfer listing, Nasdaq Staff will notify the company of delisting. Both common stock (XCYT) and 6% convertible exchangeable preferred stock (XCYTP) face delisting unless the preferred stock separately meets listing requirements.
- Appeal Process: The company may appeal a delisting determination to a Listing Qualification Panel, though success is not assured.
Investor Verification Checklist
- Verify the current trading price of XCYT and XCYTP to assess the likelihood of meeting the $1.00 bid price requirement.
- Monitor company announcements regarding any plans to transfer listing to The Nasdaq SmallCap Market.
- Review the company's capital structure to determine if the 6% convertible exchangeable preferred stock can independently meet listing standards if common stock is delisted.
- Check for subsequent filings detailing management's specific strategy to address the delisting notice.